Singlon, 5 mg 28 pcs.

Singlon is a blocker of cysteinyl leukotriene receptor CysLT1 (leukotrienes C4, D4 and E4 – mediators of chronic persistent inflammation that maintain bronchial hyperresponsiveness in bronchial asthma).

Indications

Bronchospasm, Bronchial asthmaBronchial asthma (prevention and long-term treatment), complete or incomplete combination of bronchial asthma, recurrent nasal and paranasal sinus polyposis and intolerance to ASA or others. NSAIDs (including history), bronchial asthma of physical stress, allergic rhinitis.

Active ingredient

Montelukast

Composition

One tablet contains montelukast 5 mg.

How to take, the dosage

Singlon is taken orally, regardless of meals.

Interaction

In concomitant use with phenobarbital, the AUC of montelukast decreased by approximately 40% (correction of montelukast regimen is not required).

In in vitro studies, montelukast was found to inhibit the CYP2C8 isoenzyme, but in vivo drug interaction studies of montelukast and rosiglitazone (metabolized with participation of CYP2C8 isoenzyme ) have not confirmed inhibition of CYP2C8 isoenzyme by montelukast. Therefore, in clinical practice the effect of montelukast on CYP2C8-mediated metabolism of several drugs, including paclitaxel, rosiglitazone, repaglinide, is not expected.

Montelukast is a reasonable adjunct to monotherapy with bronchodilators if the latter do not adequately control bronchial asthma. Once the therapeutic effect of montelukast treatment has been achieved, a gradual reduction in the dose of bronchodilators may be initiated.

The use of montelukast provides additional therapeutic benefit in patients receiving inhaled GCS. Once stabilization has been achieved, a gradual reduction in the dose of GCS under medical supervision may be initiated. Complete abolition of inhaled GCS is acceptable in some cases, but abrupt replacement of inhaled corticosteroids with montelukast is not recommended.

Special Instructions

The efficacy of oral montelukast for the treatment of acute attacks of bronchial asthma has not been established. Therefore, oral montelukast is not recommended for the treatment of acute attacks of bronchial asthma. Patients should be instructed to always carry emergency medications for bronchial asthma attacks (short-acting inhaled beta2-agonists).

Montelukast should not be discontinued during asthma exacerbations and when emergency medications (short-acting inhaled beta2-agonists) are needed to control attacks.

Patients with confirmed allergies to acetylsalicylic acid and other NSAIDs should not take these medications during treatment with montelukast because montelukast, while improving respiratory function in patients with allergic bronchial asthma, cannot completely prevent NSAID-induced bronchoconstriction.

The dose of inhaled GCS used concomitantly with montelukast can be decreased gradually under medical supervision, but abrupt replacement of inhaled or oral GCS with montelukast should not be performed.

In patients taking montelukast, neuropsychiatric disorders have been described. Given that these symptoms may have been caused by other factors, it is unknown whether they are related to taking montelukast. The physician should discuss these side effects with patients and/or their parents/guardians. Patients and/or caregivers should be advised that if these symptoms occur, it is important to inform the treating physician.

Dose reduction of systemic GCS in patients receiving anti-asthmatic agents, including leukotriene receptor blockers, has been accompanied in rare cases by the occurrence of one or more of the following reactions: eosinophilia, rash, worsening pulmonary symptoms, cardiac complications and/or neuropathy, sometimes diagnosed as Churg-Strauss syndrome, systemic eosinophilic vasculitis. Although a causal relationship between these adverse reactions and therapy with leukotriene receptor antagonists has not been established, caution and appropriate clinical monitoring should be exercised when decreasing the dose of systemic GCS in patients receiving montelukast.

Contraindications

Hypersensitivity, children (under 6 years).

Side effects

Blood coagulation system disorders: increased tendency to bleeding.

Immune system disorders: hypersensitivity reactions, including anaphylaxis; very rare (

Psychiatric disorders: agitation (including aggressive behavior or hostility). aggressive behavior or hostility), anxiety, depression, disorientation, pathological dreams, hallucinations, insomnia, irritability, anxiety, somnambulism, suicidal thoughts and behavior (suicidality), tremor.

Nervous system disorders: dizziness, somnolence, paresthesia/hypoesthesia; very rare (< 1/10,000) – seizures.

Cardiovascular system: tachycardia.

Respiratory system: nasal bleeding, upper respiratory tract infections.

Digestive system disorders: diarrhea, dyspepsia, nausea, vomiting, pancreatitis, increased ALT and ACT activity in blood; very rarely

Skin and subcutaneous tissue disorders: tendency to form bruises, erythema nodosa, erythema multiforme, itching, rash.

Allergic reactions: angioedema, urticaria.

Muscular system disorders: arthralgia, myalgia, including muscle cramps.

In the body in general: asthenia (weakness)/fatigue, edema, pyrexia.

Overdose

There is no specific information on the treatment of overdose with Synglon. There are no data on overdose symptoms when taking the drug in adult patients with bronchial asthma at a dose greater than 200 mg/day for 22 weeks and at a dose of 900 mg/day for 1 week.

Similarities

Singular, Montelar, Montelukast, Singlon, Montelukast, Almont, Glémont